Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) are treated with fixed-duration B-cell lymphoma 2 inhibitors + CD20 monoclonal antibodies or continuous Bruton tyrosine kinase (BTK) inhibitors. Although continuous treatment may lead to cumulative toxicity or resistance, fixed-duration treatment may lead to undertreatment and early relapse. Efficacy and safety of minimal residual disease (MRD)-guided treatment cessation of ibrutinib + venetoclax (I+V) with reinitiated I+V upon MRD conversion was evaluated in the randomized VISION/HO41 phase 2 study. Four-year follow-up including long-term toxicity and MRD kinetics are reported. Patients received ibrutinib for 2 (28-day) cycles followed by 13 cycles of I+V. Patients reaching undetectable MRD at 4 years (<10-4, flow cytometry) in the blood and bone marrow at cycle 15 (C15) were randomized 2:1 between treatment cessation with reinitiated I+V upon detectable MRD2 (dMRD2; sensitivity of ≥10-2 by flow cytometry) and ibrutinib maintenance. MRD4-positive patients at C15 remained on ibrutinib (dMRD4 arm, defined by MRD sensitivity of ≥10-4 by flow cytometry). With a median of 51.7 months, the estimated 4-year overall survival (OS) was 88%, progression free survival (PFS) was 81%; 14% of patients required next-line treatment (NT). For patients randomized to treatment cessation, 40% had reinitiated therapy per protocol because of dMRD2. No difference between treatment cessation, ibrutinib maintenance, or the dMRD4 arm continuing ibrutinib was seen for OS, PFS, or NT in landmark analysis from C15 time of randomization. Lower toxicity was demonstrated for the treatment-cessation arm. MRD-guided cessation and reinitiation of I+V for R/R CLL is feasible, reduces toxicity compared with indefinite BTK inhibitor, while providing comparable PFS rates. This trial was registered at www.clinicaltrials.gov as #NCT03226301.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2025-04-18
DOI
https://doi.org/10.1182/bloodadvances.2024015180
Citations
9
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
14.63

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Johan A. Dobber, Julie Dubois, Mark‐David Levin, Caspar da Cunha‐Bang et al.
9 citations
Blood Advances
Chronic Lymphocytic Leukemia Research
14.63
article

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Johan A. Dobber, Julie Dubois, Mark‐David Levin, Caspar da Cunha‐Bang, Anne-Marie Van Der Kevie-Kersemaekers, Henrik Frederiksen, Rogier Mous, Mattias Mattsson, Clemens Mellink, Christian Brieghel, Mar Bellido, Rene Hollestein, Gerrit-Jan Veldhuis, Sabina Kersting, Kazem Nasserinejad, Christian Bjørn Poulsen, Carsten Utoft Niemann, Wida Razawy, Arnon Philip Kater, Ann Janssens, Hoa Tran, Ellen C. Dompeling, Juha Ranti, Lisbeth Enggaard, Ida Schjødt
article en
9 citations

Abstract

Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) are treated with fixed-duration B-cell lymphoma 2 inhibitors + CD20 monoclonal antibodies or continuous Bruton tyrosine kinase (BTK) inhibitors. Although continuous treatment may lead to cumulative toxicity or resistance, fixed-duration treatment may lead to undertreatment and early relapse. Efficacy and safety of minimal residual disease (MRD)-guided treatment cessation of ibrutinib + venetoclax (I+V) with reinitiated I+V upon MRD conversion was evaluated in the randomized VISION/HO41 phase 2 study. Four-year follow-up including long-term toxicity and MRD kinetics are reported. Patients received ibrutinib for 2 (28-day) cycles followed by 13 cycles of I+V. Patients reaching undetectable MRD at 4 years (<10-4, flow cytometry) in the blood and bone marrow at cycle 15 (C15) were randomized 2:1 between treatment cessation with reinitiated I+V upon detectable MRD2 (dMRD2; sensitivity of ≥10-2 by flow cytometry) and ibrutinib maintenance. MRD4-positive patients at C15 remained on ibrutinib (dMRD4 arm, defined by MRD sensitivity of ≥10-4 by flow cytometry). With a median of 51.7 months, the estimated 4-year overall survival (OS) was 88%, progression free survival (PFS) was 81%; 14% of patients required next-line treatment (NT). For patients randomized to treatment cessation, 40% had reinitiated therapy per protocol because of dMRD2. No difference between treatment cessation, ibrutinib maintenance, or the dMRD4 arm continuing ibrutinib was seen for OS, PFS, or NT in landmark analysis from C15 time of randomization. Lower toxicity was demonstrated for the treatment-cessation arm. MRD-guided cessation and reinitiation of I+V for R/R CLL is feasible, reduces toxicity compared with indefinite BTK inhibitor, while providing comparable PFS rates. This trial was registered at www.clinicaltrials.gov as #NCT03226301.

Blood AdvancesVol. 9(15)
University Medical Center Groningen (NL), Uppsala University Hospital (SE), Utrecht University (NL), Akershus University Hospital (NO), Universitair Ziekenhuis Leuven (BE), Odense University Hospital (DK), Erasmus MC (NL), Turku University Hospital (FI), Copenhagen University Hospital (DK), Rigshospitalet (DK), University Medical Center Utrecht (NL), Zealand University Hospital (DK), Albert Schweitzer Ziekenhuis (NL), St. Antonius Ziekenhuis (NL), Amsterdam Neuroscience (NL), Netherlands Federation of University Medical Centres (NL), Haga Hospital (NL), Hovon (NL), Isala (NL), Amsterdam University Medical Centers (NL), Amsterdam University of Applied Sciences (NL), University of Amsterdam (NL)
Eli Lilly and Company, AstraZeneca, Gilead Sciences, CSL Behring, Sunesis, BeiGene, Novo Nordisk, Novo Nordisk Fonden, Cilag
Good health and well-being
Openalex Percentile: Top 1%
Chronic Lymphocytic Leukemia Research
14.63
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.